Michael Thomas Henderson, Chief Executive Officer at Apogee Therapeutics, Inc. (APGE), sold 39,900 shares at $61.93 ($2.5M) on 2025-11-13, disclosed to the SEC on 2025-11-13.
Scheduled sale ($2.5M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $61.93 | 3,340 | $207K | 8.2% |
| 2 | $61.93 | 3,340 | $207K | 8.2% |
| 3 | $63.14 | 14,774 | $933K | 37.1% |
| 4 | $63.14 | 14,774 | $933K | 37.1% |
| 5 | $63.89 | 1,786 | $114K | 4.5% |
| 6 | $63.89 | 1,786 |
| $114K |
| 4.5% |
| 7 | $64.52 | 100 | $6K | 0.3% |
| Total | $63.01 avg | 39,900 | $2.5M | 100% |
| Filing → |
| SYRE | SELL | 2026-06-23 | $2.0M | — | Filing → |
| APGE | SELL | 2026-06-12 | $1.7M | — | Filing → |
| APGE | SELL | 2026-05-15 | $1.6M | — | Filing → |